Research Topics
Genomes and Genes | A JatoiSummaryAffiliation: Mayo Clinic Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Rash from EGFR inhibitors: opportunities and challenges for palliationBenjamin M Solomon
Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Curr Oncol Rep 10:304-8. 2008..This article reviews the clinical aspects of EGFR inhibitor-induced rash, which occurs most commonly with use of these agents, and discusses some of the challenges faced in attempting palliation treatment...
Cancer chemotherapy: with or without food?Aminah Jatoi
Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Support Care Cancer 18:S13-6. 2010..as related to food or taste? What instruction should health care providers give patients about food ingestion prior to prescribing oral chemotherapy? How should we counsel patients about eating before intravenous chemotherapy?..
A pilot study of long-acting octreotide for symptomatic malignant ascitesAminah Jatoi
Mayo Clinic Rochester, Rochester, MN 55905, USA
Oncology 82:315-20. 2012..This trial explored whether octreotide, an inhibitor of vascular endothelial growth factor, a putative mediator of ascites, prolongs the interval to next paracentesis...
The positive impact of a facilitated peer mentoring program on academic skills of women facultyPrathibha Varkey
Division of Preventive and Occupational Medicine and Department of Medicine, Mayo Clinic, Rochester, MN, USA
BMC Med Educ 12:14. 2012..We describe a facilitated peer mentoring program in our institution's department of medicine...
The purported effects of alcohol on appetite and weight in lung cancer patientsAminah Jatoi
Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA
Nutr Cancer 63:1251-5. 2011..This report suggests a need for further study of alcohol as a palliative agent for cancer-associated loss of appetite and weight...
Pharmacologic therapy for the cancer anorexia/weight loss syndrome: A data-driven, practical approachAminah Jatoi
Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
J Support Oncol 4:499-502. 2006..Patients may also benefit from appetite stimulants such as corticosteroids and progestational agents,and this review summarizes the benefits of using these agents as well as their contraindications...
Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB)Aminah Jatoi
Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA
Support Care Cancer 19:1601-7. 2011..Previous studies suggest tetracycline and other antibiotics lessen the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash. This study sought to confirm such findings...
Phase II study of preoperative pemetrexed, carboplatin, and radiation followed by surgery for locally advanced esophageal cancer and gastroesophageal junction tumorsAminah Jatoi
Department of Oncology, Mayo Clinic Rochester, Rochester, Minnesota 55905, USA
J Thorac Oncol 5:1994-8. 2010..Based on favorable preliminary clinical data and the need to identify effective, well-tolerated neoadjuvant regimens for patients with locally advanced esophageal cancer, this clinical trial was undertaken...
The proteolysis-inducing factor: in search of its clinical relevance in patients with metastatic gastric/esophageal cancerA Jatoi
The Mayo Clinic, Rochester, Minnesota 55905, USA
Dis Esophagus 19:241-7. 2006..The proteolysis-inducing factor in urine does not appear to be tied to weight loss, anorexia, tumor response, or patient survival in the clinical setting of metastatic gastric/esophageal cancer...
Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment GroupAminah Jatoi
Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 23:9113-9. 2005..To answer the question, "should elderly non-small-cell lung cancer patients be offered elderly-specific trials?"..
Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment GroupA Jatoi
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Ann Oncol 17:29-34. 2006..We therefore undertook this phase II study to test this first-line combination in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia...
Omega-3 fatty acid supplements for cancer-associated weight lossAminah Jatoi
Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905 0002, USA
Nutr Clin Pract 20:394-9. 2005..This review includes a discussion of how these data might be interpreted and explained to cancer patients who are striving to cope with this syndrome...
Fish oil, lean tissue, and cancer: is there a role for eicosapentaenoic acid in treating the cancer anorexia/weight loss syndrome?Aminah Jatoi
Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Crit Rev Oncol Hematol 55:37-43. 2005....
Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment GroupAminah Jatoi
Mayo Clinic, Rochester, MN, 55905, USA
Support Care Cancer 13:381-6. 2005..The recent emergence of bortezomib, a proteasome inhibitor, now allows testing on whether proteasome inhibition is effective therapy for cancer-associated weight loss...
Exploring vitamin and mineral supplementation and purported clinical effects in patients with small cell lung cancer: results from the Mayo Clinic lung cancer cohortAminah Jatoi
Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
Nutr Cancer 51:7-12. 2005..These data suggest an association between vitamin/mineral supplementation and improved survival and point to a need for future studies on vitamin and mineral supplementation in small cell lung cancer patients...
Investigating four 'myths' surrounding dysphagia in patients with metastatic esophageal cancer. A multi-institutional study from the North Central Cancer Treatment GroupA Jatoi
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Dis Esophagus 17:292-6. 2004..Fourth, dysphagia was not associated with appetite, leptin or neuropeptide y. This study helps to dispel these four 'myths' and underscores the need for further quality of life research on dysphagia...
Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4)Aminah Jatoi
Mayo Clinic Foundation, Rochester, Minnesota 55905, USA
Oncologist 15:1016-22. 2010..Rash occurs in >50% of patients prescribed epidermal growth factor receptor (EGFR) inhibitors. This study was undertaken to determine whether sunscreen prevents or mitigates these rashes...
Interleukin-1 genetic polymorphisms and their relationship to the cancer anorexia/weight loss syndrome in metastatic gastric and gastroesophageal junction adenocarcinomaAminah Jatoi
Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
J Support Oncol 5:41-6. 2007..These preliminary data suggest that certain interleukin-1 beta genetic polymorphisms may modulate the cancer anorexia/weight loss syndrome in patients with metastatic gastric and esophageal cancer. Confirmatory studies are warranted...
Side effects and pharmaceutical company bias: adverse event reporting in cancer supportive and palliative care trialsAminah Jatoi
Mayo Clinic, Departments of Oncology, 200 First Street SW, Rochester, Minnesota 55905, USA
Expert Opin Investig Drugs 17:1787-90. 2008....
Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapyAminah Jatoi
Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA
Oncologist 13:1201-4. 2008..It suggests that quality of life issues should remain at the forefront as cancer patients and health care providers make decisions about holding cancer therapy...
A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9)Aminah Jatoi
Mayo Clinic Rochester, 200 First Street SW, Rochester, MN 55905, USA
Lung Cancer 68:234-9. 2010....
The cancer anorexia/weight loss syndrome: exploring associations with single nucleotide polymorphisms (SNPs) of inflammatory cytokines in patients with non-small cell lung cancerAminah Jatoi
Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
Support Care Cancer 18:1299-304. 2010....
Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B)Aminah Jatoi
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
J Thorac Oncol 3:516-20. 2008....
Does marital status impact survival and quality of life in patients with non-small cell lung cancer? Observations from the mayo clinic lung cancer cohortAminah Jatoi
Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
Oncologist 12:1456-63. 2007..Previous studies have found that marriage is associated with longer survival and better quality of life among lung cancer patients. The present study used the Mayo Clinic Lung Cancer Cohort to re-examine this issue...
Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044)Aminah Jatoi
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Am J Clin Oncol 30:507-13. 2007..This study tested a 3-drug, multimodality approach. Chemotherapy dose reductions, the addition of amifostine, and pharmacogenetics were tested in an effort to mitigate toxicity and predict outcomes...
A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment GroupAminah Jatoi
Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
Cancer 110:1396-403. 2007....
Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: a pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trialsAminah Jatoi
Mayo Clinic Rochester, Rochester, MN 55905, USA
Int J Oncol 36:601-6. 2010..Although age should not preclude trial entry, these adverse event rates suggest a need to develop more tolerable regimens for older patients with these malignancies...
Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147Aminah Jatoi
Mayo Clinic, Rochester, MN 55905, USA
Oncology 77:120-3. 2009..The objective of this study was to identify clinical predictors of severe rash in the hope of utilizing such factors in the design of future rash palliative and prevention trials...
A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422)A Jatoi
Mayo Clinic Rochester, 200 First Street SW, Rochester, MN 55905, USA
Ann Oncol 21:2040-4. 2010..Non-small-cell lung cancer (NSCLC) is a disease of the elderly. Seeking a tolerable but effective regimen, we tested cetuximab + radiation in elderly and/or poor performance status patients with locally advanced NSCLC...
A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment GroupAminah Jatoi
Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
Urology 69:289-94. 2007..Tomatoes are rich in lycopene. This study explored the efficacy of a lycopene-rich tomato product in androgen-independent prostate cancer and the reasons patients participated in an "alternative medicine" study...
Donepezil and vitamin E for preventing cognitive dysfunction in small cell lung cancer patients: preliminary results and suggestions for future study designsAminah Jatoi
Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
Support Care Cancer 13:66-9. 2005..Because accrual was poor, this trial also offered opportunities for suggesting other study designs for future clinical trials on cognitive dysfunction in this group of patients...
A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patientsAminah Jatoi
Division of Medical Oncology, Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Support Care Cancer 12:859-63. 2004..The safety and pharmacokinetics of infliximab in combination with docetaxel, a commonly used chemotherapy agent for non-small-cell lung cancer, were explored in this pilot study...
A phase II study of topical ceramides for cutaneous breast cancerAminah Jatoi
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Breast Cancer Res Treat 80:99-104. 2003..Short chain ceramides induce tumor cell apoptosis in preclinical models. Limited therapeutic options for patients with cutaneous breast cancer prompted the testing of these sphingolipids in patients with this disease...
A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardiaAminah Jatoi
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Int J Gastrointest Cancer 32:115-23. 2002..With the emergence of data to suggest that single agent docetaxel and irinotecan carry antineoplastic effects in this setting, we determined the response rate of these agents when given in combination...
Why should we care about the cancer anorexia/weight loss syndrome?Aminah Jatoi
Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA
Oncology (Williston Park) 17:5-6. 2003
A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinomaAminah Jatoi
Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
Cancer 97:1442-6. 2003..This Phase II trial explored green tea's antineoplastic effects in patients with androgen independent prostate carcinoma...
Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group studyAminah Jatoi
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
J Clin Oncol 20:567-73. 2002..To determine whether dronabinol administered alone or with megestrol acetate was more, less, or equal in efficacy to single-agent megestrol acetate for palliating cancer-associated anorexia...
Does megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss? A North Central Cancer Treatment Group investigationAminah Jatoi
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Support Care Cancer 10:71-5. 2002..Our investigation provides no evidence that megestrol acetate down-regulates IL-6 in patients with cancer-associated anorexia and weight loss...
An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effortAminah Jatoi
Mayo Clinic and Foundation, Rochester, MN 55905, USA
J Clin Oncol 22:2469-76. 2004..This study determined whether an EPA supplement-administered alone or with megestrol acetate (MA)-was more effective than MA...
Do patients with nonmetastatic non-small cell lung cancer demonstrate altered resting energy expenditure?A Jatoi
Department of Medicine, The New England Medical Center, Tufts University, Boston, Massachusetts, USA
Ann Thorac Surg 72:348-51. 2001..This increase in REE leads to weight loss, which in turn confers a poor prognosis. This study was undertaken to determine whether the cancer cachexia syndrome occurs in patients with nonmetastatic NSCLC...
Neuropeptide Y, leptin, and cholecystokinin 8 in patients with advanced cancer and anorexia: a North Central Cancer Treatment Group exploratory investigationA Jatoi
Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
Cancer 92:629-33. 2001..Anorexia is a noxious symptom, and over half of patients with advanced cancer experience it. Neuropeptide Y (NPY), leptin, and cholecystokinin 8 (CCK8) have been implicated...
Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB)Aminah Jatoi
Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
Cancer 113:847-53. 2008..Epidermal growth factor receptor (EGFR) inhibitors are effective cancer therapies, but they are reported to cause a rash in >50% of patients. In the current study, the authors examined the use of tetracycline for rash prevention...
Investigating the utility of serum cytokine measurements in a multi-institutional cancer anorexia/weight loss trialAminah Jatoi
Mayo Clinic and Mayo Foundation, 200 First Street, SW, Rochester, MN 55905, USA
Support Care Cancer 12:640-4. 2004..As the translational component of a large multi-institutional trial, this study assessed the clinical value of serum concentrations of these cytokines in patients with this syndrome...
Folate status among patients with non-small cell lung cancer: a case-control studyA Jatoi
Division of Hematology Oncology, Department of Medicine, New England Medical Center, Tufts University, Boston, MA, USA
J Surg Oncol 77:247-52. 2001..This case control study explored the purported inverse relationship between folate status and lung cancer development...
The prognostic effect of increased resting energy expenditure prior to treatment for lung cancerA Jatoi
Department of Medicine, The New England Medical Center, Tufts University, Boston, MA, USA
Lung Cancer 23:153-8. 1999..However, no study has validated this hypothesis to date. This study's objective was to examine the prognostic significance of REE in NSCLC...
Is Spanish language a barrier to domestic violence assessment?Aminah Jatoi
Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
J Womens Health (Larchmt) 20:1111-6. 2011..This study tested the hypothesis that language does, in fact, pose a barrier to screening and that Spanish-speaking women report lower lifetime screening rates...
Pathophysiology and palliation of inoperable bowel obstruction in patients with ovarian cancerAminah Jatoi
Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
J Support Oncol 2:323-34; discussion 334-7. 2004..This review discusses the general approach to patients with ovarian cancer and inoperable malignant bowel obstruction, with an emphasis on such palliative strategies...
Daily activities: exploring their spectrum and prognostic impact in older, chemotherapy-treated lung cancer patientsAminah Jatoi
Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
Support Care Cancer 11:460-4. 2003..to describe the daily activities of older patients as they undergo chemotherapy for incurable metastatic lung cancer...
Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment GroupK F Giordano
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Ann Oncol 17:652-6. 2006..CONCLUSIONS: The regimen docetaxel and capecitabine shows activity in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction. This regimen merits further study...
Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survivalJames M Donahue
Division of General Thoracic Surgery, Mayo Clinic, Rochester, Minnesota 55905, USA
Ann Thorac Surg 87:392-8; discussion 398-9. 2009..Neoadjuvant chemoradiotherapy followed by esophagogastrectomy has become the standard of care for patients with locally advanced esophageal cancer. This report analyzes our experience with this treatment approach...
Ramifications of severe organ dysfunction in newly diagnosed patients with small cell lung cancer: contemporary experience from a single institutionKarin F Giordano
Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
Lung Cancer 49:209-15. 2005....
A cross-sectional study of vitamin intake in postoperative non-small cell lung cancer patientsA Jatoi
Department of Medicine, Tufts University and New England Medical Center, Boston, Massachusetts 02111, USA
J Surg Oncol 68:231-6. 1998..This cross-sectional study of postoperative non-small cell lung cancer (NSCLC) patients examined possible effects of vitamin intake and folate status on disease-free survival...
Is voluntary vitamin and mineral supplementation associated with better outcome in non-small cell lung cancer patients? Results from the Mayo Clinic lung cancer cohortAminah Jatoi
Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
Lung Cancer 49:77-84. 2005..The goal of this study was to determine whether vitamin/mineral supplementation is associated with improved survival and quality of life in a cohort of NSCLC patients...
Weight loss in patients with advanced cancer: effects, causes, and potential managementAminah Jatoi
Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA
Curr Opin Support Palliat Care 2:45-8. 2008..This review provides an update of such observations and places them within the context of previous work...
A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignanciesCynthia Ma
Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Cancer Chemother Pharmacol 59:207-15. 2007..Two different treatment schedules of bortezomib in combination with paclitaxel and carboplatin were tested in this phase I study to evaluate the effects of scheduling on toxicities, pharmacodynamics and clinical activity...
Environmental tobacco smoke exposure in women with lung cancerM de Andrade
Department of Health Sciences Research, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Lung Cancer 43:127-34. 2004..We report the patterns of ETS exposure history in a clinical cohort of women with newly diagnosed lung cancer...
An update: cancer-associated anorexia as a treatment targetA Jatoi
Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
Curr Opin Clin Nutr Metab Care 4:179-82. 2001..To date, however, palliative options remain limited. Megestrol acetate and dexamethasone provide only modest relief. Novel agents such as thalidomide, adenosine triphosphate, and other cytokine inhibitors merit further investigation...
Megestrol acetate for the palliation of anorexia in advanced, incurable cancer patientsFarrah Mateen
Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Clin Nutr 25:711-5. 2006..This review focuses on these trials, summarizing their findings and providing a practical approach for prescribing megestrol acetate to advanced cancer patients who suffer from the cancer anorexia/weight loss syndrome...
Current management of cancer-associated anorexia and weight lossA Jatoi
Division of Medical Oncology Mayo Clinic, Rochester, Minnesota, USA Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA
Oncology (Williston Park) 15:497-502, 508; discussion 508-10. 2001....
Pharmacological options for advanced cancer patients with loss of appetite and weightDeepti Behl
Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA
Expert Opin Pharmacother 8:1085-90. 2007..This article reviews data to support the use of these agents, discusses the findings of other more recent studies in this field and provides an overview of promising strategies that merit further investigation...
The cancer anorexia/weight loss syndrome: therapeutic challengesKarin F Giordano
Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Curr Oncol Rep 7:271-6. 2005..As the mechanisms behind this syndrome are further elucidated, more effective therapeutic strategies will likely emerge...
Weekly carboplatin and paclitaxel in elderly non-small-cell lung cancer patients (>or=65 years of age): a phase II North Central Cancer Treatment Group studyAminah Jatoi
Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
Am J Clin Oncol 26:441-7. 2003..However, the relatively mild toxicity profile observed in this trial suggests that this regimen might remain an option for patients at increased risk for myelosuppression or with a poor performance status...
On appetite and its lossAminah Jatoi
Division of Medical Oncology and Department of Biostatistics, Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 21:79s-81s. 2003
Cumulative morbidity and late mortality in long-term survivors of exocrine pancreas cancerNisha L Jacobs
Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
J Gastrointest Cancer 40:46-50. 2009..As a result, few studies have focused on these patients' cumulative, cancer-related morbidity and late mortality. This descriptive study was undertaken to explore such issues...
Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: a phase II trial of efficacy and toxicityAnne Kanard
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Lung Cancer 43:345-53. 2004..CONCLUSIONS: Oral vinorelbine, as prescribed in this trial, provides minimal activity in the treatment of advanced non-small cell lung cancer in patients > or = 65 years of age...
Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderlySteven E Schild
Department of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
Cancer 103:2349-54. 2005..No difference in survival was identified between the two arms. The current analysis examined the relation between age and outcome for patients treated during this trial...
Cognitive dysfunction in patients with small-cell lung cancer: incidence, causes, and suggestions on managementAnne Kanard
Department of Oncology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
J Support Oncol 2:127-32; discussion 133-5, 138-40. 2004..This review provides a summary of the factors that may contribute to cognitive decline in this group of patients and comments upon how cognitive dysfunction or the risk for it might influence patient management...
Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancerEvanthia Galanis
Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
Mol Ther 16:979-84. 2008..5 months from treatment initiation. Rexin-G is well tolerated in doses up to 6 x 10(11) CFU in patients with recurrent pancreatic cancer, but there was no evidence of clinical antitumor activity...
The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderlySteven E Schild
Mayo Clinic and Mayo Foundation, Rochester, MN, USA
J Clin Oncol 21:3201-6. 2003..No difference in survival was identified between the two arms. This secondary analysis was performed to examine the relationship between patient age and outcome...
Symptom control trials: a 20-year experienceCharles L Loprinzi
Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
J Support Oncol 5:119-25, 128. 2007....
Can complementary and alternative medicine clinical cancer research be successfully accomplished? The Mayo Clinic-North Central Cancer Treatment Group experienceDebra L Barton
Mayo Clinic College of Medicine, Rochester, MN 55905, USA
J Soc Integr Oncol 4:143-52. 2006..Well-designed and adequately powered studies can be implemented, and large numbers of patients can be accrued. The resulting research evaluations can be published in peer-reviewed medical journals...
A critical look at the role of chemotherapy in older patients with non-small cell lung cancerAminah Jatoi
Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
J Thorac Oncol 2:83-90. 2007....
The effects of dietary factors on the androgen receptor and related cellular factors in prostate cancerCharles Y F Young
Department of Urology, Mayo Medical Graduate School and Mayo Graduate School, Mayo Clinic Foundation, Rochester, Minnesota, 55905, USA
Curr Med Chem 11:909-23. 2004..We further discuss the potential implication of these dietary chemicals on prevention of development and progression of prostate cancer...
Marital status and quality of life in patients with esophageal cancer or Barrett's esophagus: the mayo clinic esophageal adenocarcinoma and Barrett's esophagus registry studyRobert C Miller
Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
Dig Dis Sci 55:2860-8. 2010..Patients with esophageal carcinoma (EC) report deficits in quality of life (QOL), depending on the extent of malignant disease and the goals of treatment at the time of QOL measurement...
The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancerSteven E Schild
Department of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
Cancer 110:363-8. 2007....
Motivational readiness for physical activity and quality of life in long-term lung cancer survivorsMatthew M Clark
Department of Psychiatry and Psychology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, United States
Lung Cancer 61:117-22. 2008..Physical activity level may have important QOL and symptom management benefits for long-term lung cancer survivors...
Counseling postmenopausal women about bioidentical hormones: ten discussion points for practicing physiciansRicha Sood
Division of General Internal Medicine, Women s Health Clinic, Mayo Clinic, Rochester, MN 55905, USA
J Am Board Fam Med 24:202-10. 2011..The goal of this review is to present an overview of the available research evidence on BCHT, dispel myths about the use of compounded hormones, and provide helpful tips to answer commonly asked questions about BCHT...
Non-traumatic vertebral fractures in patients with locally advanced esophageal cancer: a previously unreported, unrecognized problemH McKean
Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Dis Esophagus 20:102-6. 2007..If confirmed, future studies should focus on identifying risk factors and optimal strategies for the prevention and treatment of vertebral fractures in patients with esophageal cancer...
Weight gain does not preclude increased ubiquitin conjugation in skeletal muscle: an exploratory study in tumor-bearing miceA Jatoi
Department of Oncology, Mayo Clinic, Rochester, Minn 55455, USA
Ann Nutr Metab 45:116-20. 2001..At least 13 studies have shown that the ubiquitin-proteasome system mediates muscle wasting in weight-losing cancer subjects. We hypothesized that cancer itself may activate the ubiquitin-proteasome system, regardless of weight loss...
Bone pain from granulocyte colony stimulating factor: does clinical trial sponsorship by a pharmaceutical company influence its reporting?Y Aldairy
Division of Hematopathology, Mayo Clinic, Rochester, MN 55905, USA
Eur J Cancer Care (Engl) 20:72-6. 2011..The reporting of adverse events from cancer symptom control and palliative care interventions should be improved - especially in trials not sponsored by pharmaceutical companies...
Aggressive multimodality therapy for patients with locally advanced esophageal cancer: is there a role for amifostine?Aminah Jatoi
Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
Semin Oncol 30:72-5. 2003....
Glutamine does not prevent paclitaxel-associated myalgias and arthralgiasStacy D Jacobson
Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
J Support Oncol 1:274-8. 2003..96). Thus this trial did not suggest any role for oral glutamine, compared with placebo, for preventing the development, or alleviating the severity, of paclitaxel-induced myalgias/arthralgias...
Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005)Michele M Corsini
Department of Radiation Oncology the Division of Gastroenterologic and General Surgery, Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 26:3511-6. 2008..To determine prognostic factors and impact of adjuvant chemotherapy (CT) and radiotherapy (RT) on overall survival (OS) after resection of pancreatic adenocarcinoma...
Do patients with schizophrenia receive state-of-the-art lung cancer therapy? A brief reportFarrah J Mateen
Department of Neurology, Mayo Clinic, Rochester, MN, USA
Psychooncology 17:721-5. 2008..Patients with schizophrenia sometimes receive substandard medical care. This study explored such disparities among lung cancer patients with underlying schizophrenia...
Curing patients with locally advanced esophageal cancer: an update on multimodality therapyK P McKian
Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Dis Esophagus 19:448-53. 2006..This review discusses recent studies in this field and outlines promising versus less promising therapeutic strategies...
Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4)Michele Y Halyard
Mayo Clinic, Scottsdale, AZ, USA
Int J Radiat Oncol Biol Phys 67:1318-22. 2007..This multi-institutional, double-blind, placebo-controlled trial was conducted to provide definitive evidence of this mineral's palliative efficacy...
Overall survival and self-reported fatigue in patients with esophageal cancerM C Stauder
Department of Radiation Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA
Support Care Cancer 21:511-9. 2013..A prospective cohort study was conducted to analyze whether self-reported fatigue predicts overall survival in patients with esophageal cancer...
Parosteal osteosarcoma from a ribA Jatoi
The Lung Tumor Evaluation Center, New England Medical Center, Tufts University, Boston, Massachusetts, USA
Ann Thorac Surg 65:265-7. 1998..Rib parosteal osteosarcomas are even rarer, with only 2 cases in the literature. We report a third such case, with a 32-month disease-free survival. Issues relevant to the management of rib parosteal osteosarcomas are discussed...
New agents, new rashes: an update on skin complications from cancer chemotherapySmitha Patiyil
Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
Curr Oncol Rep 8:269-74. 2006..It also embarks on a brief discussion of issues that investigators must face when designing clinical trials aimed at rash palliation...
Current management strategies for ovarian cancerGiovanni D Aletti
Division of Gynecologic Surgery, College of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Mayo Clin Proc 82:751-70. 2007..In this review, we provide an overview of ovarian cancer with particular emphasis on recent advances in operative management and systemic therapies...
Why do oncologists prescribe--or not prescribe--conventional chemotherapy to geriatric patients with metastatic non-small cell lung cancer?Aminah Jatoi
J Support Oncol 4:311-2. 2006
Are cancer survivors/patients knowledgeable about osteoporosis? Results from a survey of 285 chemotherapy-treated cancer patients and their companionsHeidi McKean
Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
J Nutr Educ Behav 40:144-8. 2008..This study assessed osteoporosis knowledge deficits among cancer patients and their spouses/partners...
Esophageal cancer and the esophagus: challenges and potential strategies for selective cytoprotection of the tumor-bearing organ during cancer treatmentAminah Jatoi
Department of Oncology, Mayo Comprehensive Cancer Center, Mayo Clinic Foundation, Rochester, MN, USA
Semin Radiat Oncol 12:62-7. 2002..An ongoing phase 2 trial by the North Central Cancer Treatment Group (NCCTG) may help clarify a role for cytoprotectants in patients receiving combined-modality therapy for esophageal cancer...
Does dietary counseling improve quality of life in cancer patients? A systematic review and meta-analysisThorvardur R Halfdanarson
Department of Internal Medicine, Division of Hematology, Oncology and Blood and Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City, USA
J Support Oncol 6:234-7. 2008..56 (95% confidence interval,-0.01-1.14; P = 0.06). Dietary counseling does not appear to improve QOL significantly in patients with cancer. However,an observed trend toward benefit underscores the need for further study...
Adenosine triphosphate: does it help cancer patients "get bigger and stronger"?Aminah Jatoi
J Clin Oncol 20:362-3. 2002
Who should receive parenteral nutrition or pharmacologic therapy for loss of appetite and weight in the setting of incurable cancer?Aminah Jatoi
Curr Opin Support Palliat Care 1:279-80. 2007
Research Grants
- Creatine: Is It a Body Builder for Cancer Patients?Aminah Jatoi; Fiscal Year: 2004..obtain longitudinal toxicity and quality of life data on this same cohort of 50 patients and will make direct comparisons between treatment arms on toxicity incidence and severity and on maximal quality of life scores ..
- Wine for Cancer-Associated AnorexiaAminah Jatoi; Fiscal Year: 2010..3. To explore whether wine in combination with megestrol acetate alters the hormonal milieu that modulates appetite. We will specifically look for alterations of circulating leptin, ghrelin, and neuropeptide y. ..
- Neuropeptide Y for Cancer-Associated AnorexiaAminah Jatoi; Fiscal Year: 2003..These two pilot studies will allow us to lay the groundwork for such larger trials. Our ultimate goal is to help cancer patients who suffer from anorexia. ..
- Mechanisms and Therapeutics in Cancer Anorexia/CachexiaAminah Jatoi; Fiscal Year: 2004..This K23 grant application will serve as a springboard to allow her to delve into the pathophysiology of this syndrome and to develop into an independent clinical investigator. ..
- Wine for Cancer-Associated AnorexiaAminah Jatoi; Fiscal Year: 2007..3. To explore whether wine in combination with megestrol acetate alters the hormonal milieu that modulates appetite. We will specifically look for alterations of circulating leptin, ghrelin, and neuropeptide y. ..
